A股異動 | 新開源(300109.SZ)漲逾7% 與Abcam籤戰略合作協議 做大做強體外診斷領域
格隆匯10月28日丨新開源(300109.SZ)漲逾7%,報17.56元,總市值60億元。新開源今日早間公吿,公司與Abcam於10月27日正式簽署戰略合作協議,在簽署協議後的五年期限內,Abcam將向公司提供其目錄中的親和試劑以及定製服務,供公司在體外診斷(IVD)領域的產品開發和商業化中使用。Abcam將向新開源及其關聯公司授予目錄親和試劑的非獨家許可和定製親和試劑的獨家許可,供新開源用於IVD應用、第三方機構的研發活動和新開源所開發產品的銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.